2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

TSVT 11.04.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-13
Name of Upcoming Event:Guggenheim’s Inaugural Healthcare Innovation Conference
Full Press ReleaseSEC FilingsOur TSVT Tweets

About Gravity Analytica

Recent News

  • 11.13.2024 - Guggenheim Inaugural Healthcare Innovation Conference
  • 11.12.2024 - 2seventy bio, Inc. 3Q24 Earnings Conference Call
  • 11.12.2024 - 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Recent Filings

  • 01.22.2025 - 4/A Statement of changes in beneficial ownership of securities
  • 01.10.2025 - 8-K Current report
  • 12.13.2024 - 144 Report of proposed sale of securities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2024--2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results onTuesday, November 12, 2024. A conference call and webcast will be held at8:00 a.m. ET.

Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company’s website athttps://ir.2seventybio.com. Participants who wish to ask a question may registerhereto receive dial-in numbers and a unique pin to join the call. It’s recommended that participants join 10 minutes prior to the event’s start.

Members of the management team will also be presenting at the following upcoming investor conference:

  • Guggenheim’sInaugural Healthcare Innovation ConferenceinBoston, MAonWednesday, November 13, 2024at10:00 a.m. ET

A live webcast of the fireside chat will be available via the Investors and Media section of 2seventy bio’s website athttps://ir.2seventybio.com/. Replays will be archived on 2seventy bio’s site for 30 days following the event.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visitwww.2seventybio.com.

Follow 2seventy bio on social media:X (Twitter)andLinkedIn.

2seventy bio is a trademark of2seventy bio, Inc.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241104367323/en/

Investors and Media:Vicki Eatwell, CFOvicki.eatwell@2seventybio.com

Morgan (Adams) ShieldsMorgan.adams@2seventybio.com

Source:2seventy bio, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com